4133 Stock Overview
Manufactures and sells various recombinant proteins and antibodies.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Abnova (Taiwan) Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$32.80 |
52 Week High | NT$38.85 |
52 Week Low | NT$29.80 |
Beta | 0.39 |
11 Month Change | -1.80% |
3 Month Change | 5.30% |
1 Year Change | -3.10% |
33 Year Change | -38.11% |
5 Year Change | 18.84% |
Change since IPO | -37.79% |
Recent News & Updates
Shareholder Returns
4133 | TW Life Sciences | TW Market | |
---|---|---|---|
7D | -3.2% | -2.6% | -2.3% |
1Y | -3.1% | -14.8% | 31.2% |
Return vs Industry: 4133 exceeded the TW Life Sciences industry which returned -14.9% over the past year.
Return vs Market: 4133 underperformed the TW Market which returned 31.9% over the past year.
Price Volatility
4133 volatility | |
---|---|
4133 Average Weekly Movement | 2.6% |
Life Sciences Industry Average Movement | 4.9% |
Market Average Movement | 4.7% |
10% most volatile stocks in TW Market | 8.5% |
10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 4133 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4133's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | n/a | n/a | www.abnova.com |
Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company’s products portfolio includes SARS-CoV/CoV-2 DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies.
Abnova (Taiwan) Corporation Fundamentals Summary
4133 fundamental statistics | |
---|---|
Market cap | NT$1.99b |
Earnings (TTM) | NT$59.69m |
Revenue (TTM) | NT$371.63m |
33.3x
P/E Ratio5.3x
P/S RatioIs 4133 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4133 income statement (TTM) | |
---|---|
Revenue | NT$371.63m |
Cost of Revenue | NT$201.69m |
Gross Profit | NT$169.95m |
Other Expenses | NT$110.26m |
Earnings | NT$59.69m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.99 |
Gross Margin | 45.73% |
Net Profit Margin | 16.06% |
Debt/Equity Ratio | 0.03% |
How did 4133 perform over the long term?
See historical performance and comparison